Help others to be mothers - please sign and share the Progress Educational Trust's petition, calling on the UK Government to #ExtendTheLimit on social egg freezing
Page URL: https://www.bionews.org.uk/page_91796

Gene patent enquiry triggers calls for law reform

10 August 2009
Appeared in BioNews 520

A Senate Committee in Australia is hearing arguments for and against gene patenting with a view to propose future legal reforms in this area. Opponents of gene patents argue that they can restrict access to vital diagnostic techniques, such as breast cancer screening, which identify certain genes that indicate the presence of a disorder. On the other hand, many researchers highlight the need for patents to ‘incentivise’ innovation, which in turn creates such diagnostic tests in the first place.

Some argue that as patents confer a monopoly on holders then it can deter the sharing of information in the scientific community. Addressing the Committee, Heather Drum, of the Breast Cancer Network Australia and herself a survivor of breast cancer, said: 'If someone owns a patent to one gene and someone else owns a patent to another gene associated with breast cancer, my question is, will they ever talk?' She further points out the tension between the altruistic act of donating tissue samples for scientific research and the commercial nature of patents. 'I would feel really devastated if the tissues I have donated and my sister has donated are used... to make money. If you discover a treatment or cure, then patent that. Don't patent the gene. Patent the cure,' she told the Committee. Opponents say that instances of possible restrictive behaviour arising from patents have occurred in Australia. The Age newspaper has reported that Genetic Technologies, a private company based in Melbourne, had asked health centres to cease testing for a certain gene which it held a patent over that indicated the presence of breast cancer.

In the other camp, supporters of gene patenting argue that patents are crucial to research and development. Julian Clark, head of business development at the Walter and Eliza Hall Institute, told the Committee that patents 'maximised the chance of transition' of inventions from the laboratory to a point where they are available to end-users. 'In order to maximise the invention reaching the clinic, you have to have sound intellectual property protection... Patenting is an integral part of research and setting the scene for results... no one is going to go close if they are not assured some monopoly for a certain period,' he said. He defended gene patents saying that the process of isolation and developing the gene for therapeutic use illustration them to be inventions rather than discoveries, which are not patentable.

Not everyone is convinced, however. Sally Crossing, speaking to the Committee on behalf of Cancer Voices, said: 'As an ethical principle, we do not believe that genes, as natural parts of the human body, should be patentable. We strongly recommend that Australian patent law be amended so that no part of the human body can be patented.' Dr Clark said that rather than scrapping patents the law could be reformed to set the price of licences at a reasonable level to ensure wide access to gene therapies and diagnostic testing.

The Committee will continue to hear submissions and is due to publish its report on 26 November 2009. In other developments, an organisation named the American Civil Liberties Union has filed a lawsuit in New York against against Myriad Genetics, the University of Utah Research Foundation and the US Patent and Trademark Office challenging the validity of two breast cancer gene patents: BRCA1 and BRCA2. The case is ongoing.

SOURCES & REFERENCES
Breast cancer advocates join the push for gene patent law reform
Crikey.com |  5 August 2009
Cancer survivor attacks gene patenting
The Age |  4 August 2009
Gene Patents ‘threaten cancer treatment research’
ABC News |  5 August 2009
Judge gene patents on public good, inquiry told
ABC News |  5 August 2009
The Gene Hunt: Should Finders Be Keepers?
Scientific American |  29 July 2009
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
21 February 2011 - by Gozde Zorlu 
The widespread patenting and privatisation of stem cell lines, data and technology could hinder medical research in this field, a group of scientists has warned in a paper published in Science this month....
14 June 2010 - by MacKenna Roberts 
The Australian Federal Court in Sydney is considering groundbreaking legal action of whether private companies can obtain patents on human genes....
19 April 2010 - by Harriet Vickers 
Researchers examining gene patents used in diagnostic tests say these can block competition and slow innovation, rather than spur development of new technologies for assessing the risk of genetic diseases...
8 November 2009 - by Dr Marianne Kennedy 
A lawsuit challenging the patents relating to two genes linked to hereditary breast and ovarian cancer will proceed, a US federal judge ruled last week....
18 October 2009 - by Nienke Korsten 
The US Secretary's Advisory Committee on Genetics, Health, and Society has accepted a new report from a dedicated Task Force, which recommends that scientists should be allowed to use any gene for research and patient treatment, even when it is patented....
22 May 2009 - by Heidi Colleran 
A major lawsuit in the US is challenging the right of private companies to hold patents on genes involved in diseases, as well as their right to offer exclusive genetic tests. The American Civil Liberties Union (ALCU), the Public Patent Foundation (PPF), more than a dozen universities...
14 October 2005 - by BioNews 
Nearly a fifth of all known human genes have been patented in the US, the majority by private companies, a new study reveals. The research, published in the journal Science, matched patented genes to their locations in the human genome. It showed that almost 4382 of the 23,688 genes present...
21 May 2004 - by BioNews 
The European Patent Office (EPO) has revoked a patent held by US firm Myriad Genetics, on a genetic test for hereditary breast and ovarian cancer. The ruling means that the company can no longer charge European laboratories for performing the test, which detects alterations in the BRCA1 gene. It follows...
23 February 2004 - by BioNews 
The charity Cancer Research UK (CRUK) has obtained a Europe-wide patent on the BRCA2 gene, which is involved in hereditary breast and ovarian cancer. It intends to make the patent freely available to publicly-funded laboratories across the continent, so that research and diagnostic work on the gene can continue. The...
28 October 2002 - by BioNews 
A Maltese biotechnology firm claims it has identified a loophole in the controversial patents on two genetic tests for breast cancer held by US company Myriad Genetics. Synergene says that the patents do not apply in Malta, as the country has not signed the European Patent Convention. It plans to...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.